GREGORY HAMRICK: Open Payments
NPI 1063476679 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 29 payments from 15 companies in 2025. Trend: 2023 $664 · 2024 $735 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $135 |
| Novartis Pharmaceuticals Corporation | 5 | $107 |
| Indivior Inc. | 2 | $55 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| PFIZER INC. | 1 | $16 |
Products named: Wegovy, LEQVIO, SUBLOCADE, UPTRAVI, Kerendia, MOUNJARO, REXULTI, XIFAXAN.
Industry payments across AL — which companies pay providers there.
